ALX Oncology Q1 net loss widens to $35.6M; evorpacept B-NHL data shows 83% CRR

ALX ONCOLOGY HOLDINGS INC

2024-Q1 EPS reported -$0.71

GAAP net loss $35.6M ($0.71/sh) vs $30.2M ($0.74/sh) in Q1 2023; non-GAAP loss $28.5M vs $23.8M.
Cash & investments $184.5M as of Mar 31; subsequent ATM raised ~$26.2M net; runway into Q1 2026.
Evorpacept + R2 in R/R B-NHL IST: ORR 94%, CRR 83% (historical R2 CRR 34%) in 20 patients.
Upcoming milestones: ASPEN-07 data at ASCO June 2; ASPEN-06 top line July 2024; Phase 3 init Q4 2024.
Appointed Allison Dillon, Ph.D., as Chief Business Officer.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ALX ONCOLOGY HOLDINGS INC reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 9, 2024, ALX Oncology Holdings Inc. (the "Company"), issued a press release announcing its financial results for the first quarter ended March 31, 2024.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

ALX ONCOLOGY HOLDINGS INC filing history →

Source: SEC EDGAR

accession 0000950170-24-056886

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.